Physician profile
Thomas Makres
NPI 1063513778
$1,010.60
in general payments reported to CMS, 2019-2025
11 companies · $122 in 2025
The $122 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.29 · 2020: $19.91 · 2021: $104 · 2022: $43.74 · 2023: $374 · 2024: $289 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $257.44 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $212.26 | 2019-2024 | Bexsero, Pediarix, Menveo |
| Ucb, INC. | $98.61 | 2023-2024 | Briviact, Nayzilam |
| Merck Sharp & Dohme LLC | $97.14 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $74.75 | 2019-2025 | |
| Immedica Pharma US, INC. | $69.94 | 2022-2024 | |
| Sanofi Pasteur INC. | $61.97 | 2024-2025 | |
| Abbvie INC. | $47.19 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $39.27 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $32.95 | 2024 | Flumist Quadrivalent |
| Ironshore Pharmaceuticals INC. | $19.08 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Makres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.